Indivior Pharmaceuticals, Inc.

Last updated: 25 October 2026.

What was reported

Indivior announced completion of its US redomiciliation on 26 January 2026, with a new Delaware parent. Its earlier announcement records cancellation of the secondary London listing on 25 July 2025.

Background

Indivior is a pharmaceutical company that develops treatments for opioid use disorder. Indivior, 26 January 2026. Its work includes long-acting injectable medicines. Indivior, 26 January 2026. The company identifies SUBLOCADE as part of its treatment business. Indivior, 26 January 2026.

Timeline

Report dates show when a source published its account. Event dates keep the precision given by that source.

27 June 2024 (Event): Indivior announced that its primary listing was now on Nasdaq, while its shares continued to trade in London. Investegate (RNS), 27 June 2024.
25 July 2025 (Event): Indivior announced completion of the cancellation of its secondary London listing. Indivior, 25 July 2025.
11 December 2025 (Event): Indivior’s later completion announcement records shareholder approval of the US redomiciliation on this date. Indivior, 26 January 2026.
26 January 2026 (Event): Indivior announced completion of its redomiciliation from the UK to the United States, with a new Delaware parent company. Indivior, 26 January 2026.

Type: Company
Known for: Maker of opioid-addiction treatments (Suboxone, Sublocade)
Recorded change: United States
New Delaware parent from 26 January 2026; Nasdaq trading retained after London delisting in July 2025
Status: Confirmed
Basis: Read the source account above
First reported: 22 February 2024
Sector: Healthcare (Pharmaceuticals)
Last checked: 25 October 2026

Recorded statement

No direct statement of a reason is recorded.

Wealth estimate

No sourced estimate is recorded.

Limits and uncertainty

The redomiciliation and listing changes are distinct events; they do not establish that all UK operations moved.

Latest status check: 26 January 2026. The status reflects the completed event described in the dated sources, with legal parent, listing and operating-office changes kept separate.